Role of lamivudine in the treatment of chronic hepatitis B virus infection

Annals of Pharmacotherapy

Volumn 33, Issue 10, 1999, Pages 1104-1112

  Hagmeyer, Kathleen O ^a   Pan, Yu Yuan ^b  

^a UNIVERSITY OF TOLEDO   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Hepatitis B; Immunocompetence; Lamivudine

Indexed keywords

ACICLOVIR; ALANINE AMINOTRANSFERASE; ALPHAN3 INTERFERON; ASPARTATE AMINOTRANSFERASE; GANCICLOVIR; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; PENCICLOVIR; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; VIRUS DNA;

ARTICLE; CHILL; CHRONIC HEPATITIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIARRHEA; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; FEVER; HEADACHE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNOTHERAPY; MUSCLE WEAKNESS; NAUSEA; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; VERTIGO; VOMITING;

ANTIVIRAL AGENTS; CLINICAL TRIALS; DNA, VIRAL; HEPATITIS B ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE;

EID: 0032881709     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.18452     Document Type: Article

References (37)

1. Terrault NA, Wright TL. Viral hepatitis A through G. In: Feldman M, Scharschmidt BF, Sleisenger MH, eds. Sleisenger & Fordtran's gastrointestinal and liver disease: pathophysiology, diagnosis, management. 6th ed., vol. 2. Philadelphia: WB Saunders Co., 1998:1123-70.
2. Dienstag JL, Isselbacher KJ. Acute viral hepatitis. In: Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JJ, Kasper DL, et al., eds. Harrison's principles of internal medicine. 14th ed. New York: McGraw-Hill, 1998:1677-92.
3. Dienstag JL, Isselbacher KJ. Chronic hepatitis. In: Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JJ, Kasper DL, et al., eds. Harrison's principles of internal medicine. 14th ed. New York: McGraw-Hill, 1998:1696-704.
4. Margolis HS, Alter MJ, Hadler SC. Hepatitis B: evolving epidemiology and implications for control. Semin Liver Dis 1991;11:84-92.
5. Lee WM. Hepatitis B virus infection. N Engl J Med 1997;337:1733-45.
6. Hepatitis surveillance: viral hepatitis surveillance program. Atlanta: Centers for Disease Control and Prevention, 1996:56. www.cdc.gov/ncidod/ diseases/hepatitis/h96surve.htm.
7. Hoofnagle JH, Di Bisceglie AM. The treatment of chronic viral hepatitis. N Engl J Med 1997;336:347-56.
8. Fried MW. Therapy of chronic viral hepatitis. Med Clin North Am 1996;80:957-72.
9. Hoofnagle JH. Therapy of viral hepatitis. Digestion 1998;59:563-78.
10. Woo MH, Burnakis TG. Interferon alfa in the treatment of chronic viral hepatitis B and C. Ann Pharmacother 1997;31:330-7.
11. Saracco G, Rizzetto M. A practical guide to the use of interferons in the management of hepatitis virus infections. Drugs 1997;53:74-85.
12. Perrillo RP. Factors influencing response to interferon in chronic hepatitis B: implications for Asian and Western populations. Hepatology 1990; 12:1433-5.
13. Perry CM, Faulds D. Lamivudine: a review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in the management of HIV infection. Drugs 1997;53:657-80.
14. Johnson MA, Horak J, Breuel P. The pharmacokinetics of lamivudine in patients with impaired hepatic function. Eur J Clin Pharmacol 1998;54: 363-6.
15. Product information. Epivir (lamivudine). Research Triangle Park, NC: Glaxo Wellcome Inc., 1997.
16. Fontana RJ, Lok AS. Combination therapy for chronic hepatitis B. Hepatology 1997;26:234-7.
17. Dienstag JL, Perrillo RP, Schiff ER, Bartholomew M, Vicary C, Rubin M. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 1995;333:1657-61.
18. Lai CL, Ching CK, Tung AK, Li E, Young J, Hill A, et al. Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers: a placebo-controlled trial. Hepatology 1997;25: 241-4.
19. Nevens F, Main J, Honkoop P, Tyrrell L, Barber J, Sullivan MT, et al. Lamivudine therapy for chronic hepatitis B: a six-month randomized dose-ranging study. Gastroenterology 1997;113:1258-63.
20. Honkoop P, de Man RA, Zondervan PE, Schalm SW. Histological improvement in patients with chronic hepatitis B virus infection treated with lamivudine. Liver 1997;17:103-6.
21. Lai CL, Liaw YF, Leung NW, Chang TT, Guan R, Tai DI, et al. A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998;339: 61-8.
22. Mutimer D, Naoumov N, Honkoop P, Marinos G, Ahmed M, de Man R, et al. Combination alpha-interferon and lamivudine therapy for alpha-interferon - resistant chronic hepatitis B infection: results of a pilot study. J Hepatol 1998;28:923-9.
23. Gish RG, Lau JY, Brooks L, Fang JW, Steady SL, Imperial JC, et al. Ganciclovir treatment of hepatitis B virus infection in liver transplant recipients. Hepatology 1996;23:1-7.
24. Shaw T, Mok SS, Locarnini SA. Inhibition of hepatitis B virus DNA polymerase by enantiomers of penciclovir triphosphate and metabolic basis for selective inhibition of HBV replication by penciclovir. Hepatology 1996;24:996-1002.
25. Colledge D, Locarnini S, Shaw T. Synergistic inhibition of hepadnaviral replication by lamivudine in combination with penciclovir in vitro. Hepatology 1997;26:216-25.
26. Honkoop P, Niesters HG, de Man RA, Osterhaus AD, Schalm SW. Lamivudine resistance in immunocompetent chronic hepatitis B. Incidence and patterns. J Hepatol 1997;26:1393-5.
27. Aye TT, Bartholomeusz A, Shaw T, Bowden S, Breschkin A, McMillan J, et al. Hepatitis B virus polymerase mutations during antiviral therapy in a patient following liver transplantation. J Hepatol 1997;26:1148-53.
28. Ling R, Mutimer D, Ahmed M, Boxall EH, Elias E, Dusheiko GM, et al. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology 1996;24:711-3.
29. Tipples GA, Ma MM, Fischer KP, Bain VG, Kneteman NM, Tyrrell DL. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology 1996;24:714-7.
30. Allen MI, Deslauriers M, Andrews CW, Tipples GA, Walters KA, Tyrrell DL, et al. Identification and characterization of mutations in hepatitis B virus resistance to lamivudine. Hepatology 1998;27:1670-7.
31. Bain VG, Kneteman NM, Ma MM, Gutfreund K, Shapiro JA, Fischer K, et al. Efficacy of lamivudine in chronic hepatitis B patients with active viral replication and decompensated cirrhosis undergoing liver transplantation. Transplantation 1996;62:1456-62.
32. Grellier L, Mutimer D, Ahmed M, Brown D, Burroughs AK, Rolles K, et al. Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis. Lancet 1996;348:1212-5.
33. Ben-Ari Z, Shmueli D, Mor E, Shapira Z, Tur-Kaspa R. Beneficial effect of lamivudine in recurrent hepatitis B after liver transplantation. Transplantation 1997;63:393-6.
34. Benhamou Y, Katlama C, Lunel F, Coutellier A, Dohin E, Hamm N, et al. Effects of lamivudine on replication of hepatitis B virus in HIV-infected men. Ann Intern Med 1996;125:705-12.
35. Al Faridy K, Yoshida EM, Davis JE, Vartanian RK, Anderson FH, Steinbrecher UP. Alteration of the dismal natural history of fibrosing cholestatic hepatitis secondary to hepatitis B virus with the use of lamivudine. Transplantation 1997;64:926-8.
36. Chan TM, Wu PC, Li FK, Lai CL, Cheng IK, Lai KN. Treatment of fibrosing cholestatic hepatitis with lamivudine. Gastroenterology 1998; 115:177-81.
37. Honkoop P, de Man RA, Niesters HG, Main J, Nevens F, Thomas HC, et al. Quantitative hepatitis B virus DNA assessment by the limiting-dilution polymerase chain reaction in chronic hepatitis B patients: evidence of continuing viral suppression with longer duration and higher dose of lamivudine therapy (abstract). J Viral Hepat 1998;5:307-12.